BR112018010759A2 - composições farmacêuticas, processo para preparação de composição farmacêutica, e, método de tratamento curativo ou profilático - Google Patents

composições farmacêuticas, processo para preparação de composição farmacêutica, e, método de tratamento curativo ou profilático

Info

Publication number
BR112018010759A2
BR112018010759A2 BR112018010759A BR112018010759A BR112018010759A2 BR 112018010759 A2 BR112018010759 A2 BR 112018010759A2 BR 112018010759 A BR112018010759 A BR 112018010759A BR 112018010759 A BR112018010759 A BR 112018010759A BR 112018010759 A2 BR112018010759 A2 BR 112018010759A2
Authority
BR
Brazil
Prior art keywords
curative
preparing
prophylactic treatment
pharmaceutical composition
pharmaceutical compositions
Prior art date
Application number
BR112018010759A
Other languages
English (en)
Inventor
Parsottam Kansagra Bipin
Prakashrao Sadaphal Krishna
Shivajirao Deshmukh Nitin
Kumar Dwivedi Rajesh
Bhaskar Bhirud Shekhar
Kantilal Kale Shrikrishna
Mahadev Kadam Suresh
Rameshchandra Dhuppad Ulhas
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63039388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018010759(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of BR112018010759A2 publication Critical patent/BR112018010759A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Abstract

a presente invenção refere-se a formulações farmaceuticamente aceitáveis compreendendo sais de oxalato de teneligliptina e solvatos dos mesmos. também são providas combinações com biguanidas e uso das ditas formulações farmaceuticamente aceitáveis para a gestão de distúrbios do metabolismo da glicose.
BR112018010759A 2017-02-03 2018-02-02 composições farmacêuticas, processo para preparação de composição farmacêutica, e, método de tratamento curativo ou profilático BR112018010759A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721004095 2017-02-03
PCT/IB2018/050662 WO2018142334A1 (en) 2017-02-03 2018-02-02 Formulations comprising oxalate salts of teneligliptin and solvates thereof

Publications (1)

Publication Number Publication Date
BR112018010759A2 true BR112018010759A2 (pt) 2018-12-04

Family

ID=63039388

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018010759A BR112018010759A2 (pt) 2017-02-03 2018-02-02 composições farmacêuticas, processo para preparação de composição farmacêutica, e, método de tratamento curativo ou profilático
BR112018010748A BR112018010748A2 (pt) 2017-02-03 2018-02-02 ?sal de oxalato, forma cristalina de um composto, forma amorfa de um composto, composto, processos para obter sal de oxalato e um composto e para preparar um composto, distúrbio do metabolismo de glicose, e, método de tratamento profilático ou curativo do distúrbio do metabolismo de glicose?

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112018010748A BR112018010748A2 (pt) 2017-02-03 2018-02-02 ?sal de oxalato, forma cristalina de um composto, forma amorfa de um composto, composto, processos para obter sal de oxalato e um composto e para preparar um composto, distúrbio do metabolismo de glicose, e, método de tratamento profilático ou curativo do distúrbio do metabolismo de glicose?

Country Status (10)

Country Link
JP (2) JP2019508385A (pt)
KR (2) KR20180100554A (pt)
CN (2) CN108697707A (pt)
AU (2) AU2018202623A1 (pt)
BR (2) BR112018010759A2 (pt)
EA (1) EA039402B1 (pt)
MX (2) MX2018006006A (pt)
RU (2) RU2018120216A (pt)
TW (2) TW201831473A (pt)
WO (2) WO2018142334A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020209350A1 (ja) * 2019-04-12 2020-10-15 田辺三菱製薬株式会社 糖尿病治療用口腔内速崩壊錠
CN110028496A (zh) * 2019-04-26 2019-07-19 梯尔希（南京）药物研发有限公司 一种特力利汀相关杂质的合成方法
WO2021053564A1 (en) * 2019-09-17 2021-03-25 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising remogliflozin or salt or ester thereof and teneligliptin or salt thereof
KR20210121421A (ko) 2020-03-30 2021-10-08 코오롱생명과학 주식회사 테네리글리프틴 2.5브롬화수소산염 무정형의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319322B (en) * 2003-11-13 2010-01-11 Ono Pharmaceutical Co Frozen-dried preperation containing prostaglandin
CN102372705A (zh) * 2005-02-18 2012-03-14 田边三菱制药株式会社 脯氨酸衍生物的盐，其溶剂合物，及其生产方法
CA2752437C (en) * 2009-02-13 2017-07-11 Boehringer Ingelheim International Gmbh Antidiabetic medications
NZ599298A (en) * 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
ES2596324T3 (es) * 2009-12-18 2017-01-05 Mitsubishi Tanabe Pharma Corporation Preparación de teneligliptina con elución estabilizada
US9518048B2 (en) * 2012-08-31 2016-12-13 Glenmark Pharmaceuticals Limited Process for the preparation of teneligliptin
JP6088872B2 (ja) * 2013-03-22 2017-03-01 サラヤ株式会社 ラクトン型ソホロリピッドの分解が抑制されたソホロリピッド粉末
WO2015012365A1 (ja) * 2013-07-25 2015-01-29 株式会社 三和化学研究所 医薬製剤
WO2015019238A1 (en) * 2013-08-06 2015-02-12 Ranbaxy Laboratories Limited Process for the preparation of n-protected (5s)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-one
CN104650065A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 一种替格列汀化合物
WO2015132679A1 (en) * 2014-03-05 2015-09-11 Glenmark Pharmaceuticals Ltd Teneligliptin compositions
WO2015173779A1 (en) * 2014-05-16 2015-11-19 Micro Labs Limited Process for the preparation of teneligliptin and its novel intermediates
CN105294673B (zh) * 2014-06-18 2018-04-13 四川科伦药物研究院有限公司 一种氢溴酸替格列汀的合成方法
WO2016051368A1 (en) * 2014-10-01 2016-04-07 Mylan Laboratories Ltd Complex of amorphous empagliflozin and a cyclodextrin
JP6027710B1 (ja) * 2014-12-25 2016-11-16 田辺三菱製薬株式会社 糖尿病治療用固形製剤

Also Published As

Publication number Publication date
TW201831473A (zh) 2018-09-01
WO2018142327A1 (en) 2018-08-09
MX2018006006A (es) 2019-05-16
JP2019508385A (ja) 2019-03-28
AU2018202623A1 (en) 2018-08-23
TW201834655A (zh) 2018-10-01
KR20180099635A (ko) 2018-09-05
EA201992376A1 (ru) 2020-03-23
BR112018010748A2 (pt) 2018-12-04
RU2742418C1 (ru) 2021-02-05
RU2018120216A (ru) 2021-05-07
MX2018006005A (es) 2019-05-16
EA039402B1 (ru) 2022-01-24
JP2019512460A (ja) 2019-05-16
WO2018142334A1 (en) 2018-08-09
KR20180100554A (ko) 2018-09-11
CN108884089A (zh) 2018-11-23
AU2018202960A1 (en) 2018-08-23
CN108697707A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
BR112018010759A2 (pt) composições farmacêuticas, processo para preparação de composição farmacêutica, e, método de tratamento curativo ou profilático
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112019024747A2 (pt) formulações de dose fixa
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
BR112022017393A2 (pt) Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto
BR112018068565A2 (pt) combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112019009529A2 (pt) novos derivados de quinolina
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112018010018A2 (pt) moduladores de ror-gama
BR112017024933A2 (pt) alvocidib produce com a bioavailabilidade aumentada
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
BR112015018087A8 (pt) composto, composição farmacêutica e uso
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112018069930A2 (pt) agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos
BR112018017031A2 (pt) formulações de antagonista de il-6 e usos das mesmas
BR112017026272A2 (pt) ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto?
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112017009510A2 (pt) composições compreendendo ciclosporina
BR112017019358A2 (pt) combinações e formulações de dose fixa compreendendo etc1002 e ezetimiba e métodos de tratamento ou redução do risco de doença cardiovascular

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2620 DE 23/03/2021.